SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BBOT

BridgeBio Oncology Therapeutics, Inc. (BBOT)

NASDAQ: BBOT · USD
Healthcare · Biotechnology
$1.81-$0.05 (-2.69%)
 
Market cap
$145M
Insider Score
Analyst consensus
Website
Market Cap$145.25M-85.1%
Revenue (ttm)n/a
Net Income-$171.53M
EPS$0.53
Shares Out80.25M
PE Ratio3.42
Forward PE-0.87
Dividendn/a
Ex-Dividend Daten/a
Volume450,960
Open$1.87
Previous Close$1.86
Day's Range$1.78 - $1.94
52-Week Range$1.78 - $14.87
Beta0.85
AnalystsStrong Buy
Price Target$20.91(+1055.20%)
Earnings DateNov 10, 2026
-2.69% (1D)
No price history available.

About BBOT

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Address
256 East Grand Avenue, South San Francisco, CA, 94080, United States
Market Cap
145 million
Employees
84
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.63K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
9 Buy0 Hold0 SellAvg target $22.67 (+1156.0%)

9 firms rating BBOT in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-2.69%
5 Days
-15.42%
1 Month
-36.49%
6 Months
-78.83%
1 Year
-85.14%

$BBOT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BBOT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BBOT's directors and management

Net Shares Purchased by Insiders−2k−1k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BBOT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New BBOT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BBOT from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from BBOT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
2
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.24%
XBIState Street SPDR S&P Biotech ETF0.02%
IBBiShares Biotechnology ETF0.01%
PWSPacer WealthShield ETF0.00%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.00%

Weight is the stock’s share of each fund’s holdings.